GMAB News - Candlesense

Genmab to Participate in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference

Media Release COPENHAGEN, Denmark; August 26, 2025 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan Van de Winkel and Chief Financial Officer Anthony Pagano will parti...

Conference

2 days ago

Genmab Receives FDA Breakthrough Therapy Designation for Rinatabart Sesutecan (Rina-S®) in Advanced Endometrial Cancer (EC)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to rinatabart ses...

What competitive landscape does Rina‑S face in endometrial cancer and how might its efficacy compare to existing therapies? How will the Breakthrough Therapy Designation impact Genmab's valuation and stock price in the short term? What is the expected timeline for further clinical milestones and potential FDA approval following the Breakthrough Therapy Designation?

Clinical

2 days ago

Genmab Announces Phase 3 EPCORE® FL-1 Clinical Trial Met Dual Primary Endpoints in Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL)

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) today announced positive results of the Phase 3 EPCORE® FL-1 trial evaluating subcutaneous epcoritamab, a bispecific antibody, in com...

Will the dual primary endpoints lead to an upgrade in analyst coverage or target price revisions by sell‑side analysts? How does the efficacy of the epcoritamab+R2 combo influence potential market share against competing bispecifics like Blincyto (blinatumomab) or other emerging FL therapies? Are there any upcoming catalyst events (e.g., FDA advisory committee, submission dates) we should watch for?

Clinical trials

21 days ago